

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Peijia Medical Limited **沛嘉醫療有限公司**

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 9996)

VOLUNTARY ANNOUNCEMENT

UNAUDITED OPERATING STATISTICS FOR THE YEAR ENDED DECEMBER 31, 2025

This announcement is made by Peijia Medical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to provide the shareholders of the Company and potential investors with updated information in relation to the latest business and product development progress of the Group.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce certain unaudited operating statistics of the Group for the year ended December 31, 2025 (the “**Reporting Period**”), and the comparative figures as set out below.

	For the period from January 1 to December 31,		
	2025 <i>RMB'million</i>	2024 <i>RMB'million</i>	Change <i>%</i>
Revenue	Approximately 700.0–720.0	615.5	Approximately 13.7–17.0

The Group’s sustained revenue growth was primarily attributable to: (i) the strong performance across all three product lines of the neurointerventional business; and (ii) ongoing market share expansion in China’s transcatheter aortic valve replacement (“**TAVR**”) market, particularly driven by the successful launch of the premium TaurusMax® 3D-Steerable TAVR System.

All three major neurointerventional product lines recorded solid revenue growth, reflecting the strong performance of their respective core products. The key drivers are summarized as follows:

- a. Vascular access products recorded revenue growth, primarily driven by continued volume expansion of the high-performance DCwire® Micro Guidewire, resulting in a rapid increase in market share;
- b. Hemorrhagic products benefited from the successful launch of the YonFlow® Flow Diverting Stent, contributing to revenue growth of the product line;
- c. Ischemic products achieved revenue growth mainly attributable to increased sales volumes of the Syphonet® Stent Retriever and Tethy AS® Aspiration Catheter. Within the ischemic portfolio, following the implementation of volume-based procurement in the second half of 2025, despite the selling price reductions in balloon dilatation catheters, sales volumes increased significantly, particularly for the Fastunnel® Delivery Balloon Dilatation Catheter, resulting in overall revenue stability of balloon dilatation catheters compared with 2024.

During the Reporting Period, the Group's commercialized TAVR portfolio — comprising TaurusOne®, TaurusElite® and TaurusMax® TAVR Systems for aortic stenosis nationwide, and Trilogy™ Transcatheter Heart Valve System for aortic regurgitation in Hong Kong and Taiwan, China — expanded into approximately 130 additional hospitals, bringing cumulative coverage to over 780 hospitals as of December 31, 2025.

Total implantations during the Reporting Period were approximately 3,900 units, representing a year-on-year growth of 14.4% and significantly outperforming the overall market growth rate. Following the approval by the National Medical Products Administration of the registration application for the TaurusTrio® Transcatheter Aortic Valve System in December 2025, the Company expects to commence comprehensive commercialization in China's aortic regurgitation market.

As of the date of this announcement, the Company is still in the process of preparing and finalizing the annual results of the Group for the Reporting Period. The above operating information is preliminary unaudited information that has not been reviewed, confirmed or audited by the auditors of the Company, nor reviewed by the audit committee of the Board, and is provided for investors' reference only and it shall not be taken as a measure or indication of the Group's future financial performance. Shareholders and potential investors are advised to read carefully the announcement of the Company in relation to the results of the Group for the Reporting Period, which is expected to be published in March 2026 in accordance with the requirements of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

SHAREHOLDERS OF THE COMPANY AND POTENTIAL INVESTORS ARE ADVISED TO EXERCISE CAUTION WHEN DEALING IN THE SHARES OF THE COMPANY.

By order of the Board
Peijia Medical Limited
Dr. Yi ZHANG

Chairman and Executive Director

Hong Kong, February 6, 2026

As of the date of this announcement, the Board comprises Dr. Yi ZHANG, Mrs. Ping Ye ZHANG and Ms. Hong YE as executive Directors, Mr. Jifeng GUAN, Mr. Fei CHEN, Mr. Jun YANG as non-executive Directors, and Dr. Stephen Newman OESTERLE, Mr. Robert Ralph PARKS, Mr. WaiMing YIP and Mr. Huacheng WEI as independent non-executive Directors.